PI-02: FOLLOW-UP RESULTS OF A PHASE 2 STUDY ASSESSING THE SAFETY AND EFFICACY OF MITAPIVAT TREATMENT, AN ORAL PYRUVATE KINASE ACTIVATOR, FOR UP TO 60 WEEKS IN SUBJECTS WITH SICKLE CELL DISEASE.

Autor:	M., VAN DIJK, M., RAB, B., VAN OIRSCHOT, J., BOS, C., DERICHS, A., RIJNEVELD, M., CNOSSEN, E., NUR, B., BIEMOND, M., BARTELS, J., JANS, W., VAN SOLINGE, R., SCHUTGENS, R., VAN WIJK, E., VAN BEERS
Zdroj:	HemaSphere; 2022 Supplement 4, Vol. 6, p9-10, 2p
Databáze:	Complementary Index
Externí odkaz:	Zobrazit plný text záznamu Plný text